Browse EyeWorld Weekly ophthalmology news on EyeWorld.org. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ FDA accepts NDA for pupil dilation spray ➤ NDA for new glaucoma drug accepted ➤ PMA application submitted to FDA for new IOL ➤ Data report: 12-month efficacy seen from single mechanical MGD treatment ➤ Acquisition of company developing drugs for rare ophthalmic diseases ➤ ASCRS news and events
➤ NDA submitted to FDA for drug that reverses mydriasis ➤ FDA cleared IND application for gene therapy to treat form of Leber congenital amaurosis ➤ FDA approves IND for research to move forward on RP gene therapy ➤ Phase 2 study to treat geographic atrophy begins ➤ Study: Weaning patients off of AMD treatments compared ➤ Possible geographic atrophy treatment explored ➤ ASCRS news and events
➤ NDA submitted for new, topical dry eye disease treatment ➤ IND submitted for persistent corneal epithelial defect treatment ➤ IND filed for dry eye disease treatment ➤ Study: Investigational topical drop reduces inflammation in anterior uveitis cases ➤ Alcon completes acquisition of Aerie ➤ ASCRS news and events
➤ FDA approves AI-based diabetic retinopathy screener ➤ FDA accepts NDA for Demodex treatment ➤ Phase 2b results for MGD therapy ➤ Phase 1/2 trial evaluates investigational TED treatment ➤ Phase 1 clinical trial to study synthetic cannabinoid derivative for glaucoma ➤ OCT company rebrands ➤ ASCRS news and events
➤ Phase 1/2a results for suprachoroidal wet AMD treatment ➤ Enrollment complete for two Phase 2 trials investigating dry eye therapies disease ➤ Phase 2b study for drug-eluting contact lens begins ➤ Healthcare company acquires biopharmaceutical company developing ophthalmic treatments ➤ Development and commercialization licensing agreement ➤ ASOA podcast features dry eye info for the practice ➤ ASCRS news and events
➤ Topline results from Phase 3 study of atropine for myopia progression ➤ Phase 3 results for novel glaucoma drop ➤ Positive results from two Phase 3 studies for patients with RVO ➤ Phase 3 results for cell therapy treating macular telangiectasia type 2 ➤ Single injection of investigational compound for DME improves BCVA ➤ FDA accepts BLA for ophthalmic bevacizumab ➤ Mobile phone attachment developed for ophthalmic clinical trials ➤ ASCRS news and events
➤ FDA accepts NDA for ‘first-of-its-kind’ anti-inflammatory for dry eye ➤ Positive Phase 3 results for investigational presbyopia therapy ➤ Study: long-term visual outcomes with remote monitoring technology ➤ Companies partner to create tool to assess fall risk ➤ ASCRS news and events
➤ CDC reports cases of ocular monkeypox ➤ Recall of intravitreal implant ➤ NDA filed for nanoemulsion for postop inflammation and pain ➤ Companies partner to enhance visual assessment technology ➤ Companies enter into business combination agreement ➤ ASCRS news and events
➤ NDA submitted to FDA for once-daily glaucoma drop ➤ Positive Phase 3 data for novel preservative-free latanoprost delivery method ➤ Phase 4 DME safety study reduces need for treatments ➤ New data from Phase 3 trial for investigational Acanthamoeba keratitis treatment ➤ New findings on visual potential for adults with Leber congenital amaurosis ➤ ASCRS news and events
➤ FDA approves new therapy for amblyopia ➤ First-in-human data from IOL/drug-delivery platform ➤ Largest crosslinking study to date for keratoconus ➤ Interim data for Phase 2 trial evaluating choroidal melanoma treatment ➤ Gene therapy update ➤ SLT trial seeking more clinical sites, deadline October 14 ➤ Acquisition news ➤ ASCRS news and events